Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging

Gynecologic and Obstetric Investigation

Volumn 72, Issue 4, 2011, Pages 252-256

  Kajiyama, Hiroaki ^a   Shibata, Kiyosumi ^a   Suzuki, Shiro ^a   Ino, Kazuhiko ^c   Kawai, Michiyasu ^d   Nagasaka, Tetsuro ^b   Nawa, Akihiro ^e   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^e EHIME UNIVERSITY   (Japan)

Author keywords

Cisplatin; Clear cell carcinoma; Epithelial ovarian cancer; Paclitaxel; Prognosis

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; EARLY STAGE OVARIAN CLEAR CELL CARCINOMA; HUMAN; HUMAN CELL; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 83555166071     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000327924     Document Type: Article

References (17)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6. (Pubitemid 26012496)
2. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465. (Pubitemid 46606325)
3. Bristow RE, Montz FJ, Lagasse LD, et al: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72: 278-287. (Pubitemid 29118182)
4. Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinumbased chemotherapy. Cancer 2000; 88: 2584-2589. (Pubitemid 30331967)
5. Kennedy AW, Biscotti CV, Hart WR, et al: Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-349. (Pubitemid 19074926)
6. Goff BA, Sainz de la Cuesta R, Muntz HG, et al: Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60: 412-417. (Pubitemid 26077628)
7. Czernobilsky B, Silverman BB, Enterline HT: Clear-cell carcinoma of the ovary: a clinicopathologic analysis of pure and mixed forms and comparison with endometrioid carcinoma. Cancer 1970; 25: 762-772.
8. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996; 23: 40-47. (Pubitemid 26391379)
9. Ho CM, Huang YJ, Chen TC, et al: Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinumbased chemotherapy in pure-type advanced disease. Gynecol Oncol 2004; 94: 197-203.
10. Recio FO, Piver MS, Hempling RE, et al: Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996; 78: 2157-2163. (Pubitemid 26367609)
11. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-1150.
12. Kita T, Kikuchi Y, Kudoh K, et al: Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 2000; 7: 327-331.
13. Ohta I, Gorai I, Miyamoto Y, et al: Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells. Cancer Lett 2001; 162: 39-48.
14. Behbakht K, Randall TC, Benjamin I, et al: Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70: 255-258. (Pubitemid 28430939)
15. Utsunomiya H, Akahira J, Tanno S, et al: Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 2006; 16: 52-56.
16. Nishino K, Aoki Y, Amikura T, et al: Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 2005; 97: 893-897. (Pubitemid 40824662)
17. Takano M, Sugiyama T, Yaegashi N, et al: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol 2007; 12: 256-260. (Pubitemid 47262735)